Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 3 | 1 |
| List of Figures | 4 | 1 |
| Report Guidance | 5 | 1 |
| Clinical Trials by Region | 6 | 8 |
| Clinical Trials and Average Enrollment by Country | 7 | 2 |
| Top Five Countries Contributing to Clinical Trials in Asia-Pacific | 9 | 1 |
| Top Five Countries Contributing to Clinical Trials in Europe | 10 | 1 |
| Top Countries Contributing to Clinical Trials in North America | 11 | 1 |
| Top Countries Contributing to Clinical Trials in Middle East and Africa | 12 | 1 |
| Top Five Countries Contributing to Clinical Trials in Central and South America | 13 | 1 |
| Clinical Trials by G7 Countries: Proportion of Cystic Fibrosis to Respiratory Clinical Trials | 14 | 1 |
| Clinical Trials by Phase in G7 Countries | 15 | 1 |
| Clinical Trials in G7 Countries by Trial Status | 16 | 1 |
| Clinical Trials by E7 Countries: Proportion of Cystic Fibrosis to Respiratory Clinical Trials | 17 | 1 |
| Clinical Trials by Phase in E7 Countries | 18 | 1 |
| Clinical Trials in E7 Countries by Trial Status | 19 | 1 |
| Clinical Trials by Phase | 20 | 2 |
| In Progress Trials by Phase | 21 | 1 |
| Clinical Trials by Trial Status | 22 | 1 |
| Clinical Trials by End Point Status | 23 | 1 |
| Subjects Recruited Over a Period of Time | 24 | 1 |
| Clinical Trials by Sponsor Type | 25 | 1 |
| Prominent Sponsors | 26 | 3 |
| Top Companies Participating in Cystic Fibrosis Therapeutics Clinical Trials | 27 | 2 |
| Prominent Drugs | 29 | 1 |
| Latest Clinical Trials News on Cystic Fibrosis | 30 | 8 |
| Aug 16, 2016: Anthera Pharmaceuticals Announces Positive DSMB Review in Phase 3 SOLUTION Study of Sollpura | 30 | 1 |
| Aug 15, 2016: Vertex Provides Update on Ongoing Phase 3 Program for VX-661 in Combination with Ivacaftor for the Treatment of Cystic Fibrosis | 30 | 1 |
| Jul 15, 2016: Pharmaxis Completes Recruitment of Pivotol Bronchitol Cystic Fibrosis Clinical Trial for US Market | 31 | 1 |
| Jul 07, 2016: Nivalis Therapeutics Announces Completion of Enrollment in Phase 2 Study of N91115 for Treatment of Cystic Fibrosis | 31 | 1 |
| Jul 07, 2016: Protalix BioTherapeutics Announces First Patient Dosed in the AIR DNase Phase II Clinical Trial for Cystic Fibrosis | 32 | 1 |
| Jun 21, 2016: ProQR to Release Topline Data from Proof of Concept Study of QR-010 in Cystic Fibrosis Patients at NACFC | 32 | 1 |
| Jun 10, 2016: Vertex Announces Presentation of Data for KALYDECO (ivacaftor) at European Cystic Fibrosis Society Conference | 33 | 1 |
| Jun 10, 2016: Vertex Announces Presentation of Data for ORKAMBI (lumacaftor/ivacaftor) at European Cystic Fibrosis Society Conference | 34 | 1 |
| Jun 10, 2016: Raptor Pharmaceutical Announces Presentation of New Data Analyses from a Phase 3 Study of QUINSAIR at the 39th European Cystic Fibrosis Conference | 35 | 1 |
| Jun 10, 2016: New Analyses from Phase 3 Study 009 of Translarna (ataluren) in Patients with Cystic Fibrosis Presented at 39th European Cystic Fibrosis Conference | 36 | 1 |
| Jun 10, 2016: Concert Pharmaceuticals Presents CTP-656 Phase 1 Results at European Cystic Fibrosis Conference | 36 | 1 |
| Jun 07, 2016: Raptor Pharmaceutical to Present Data on QUINSAIR at European Cystic Fibrosis Conference | 37 | 1 |
| Clinical Trial Profile Snapshots | 38 | 415 |
| Appendix | 453 | 3 |
| Abbreviations | 453 | 1 |
| Definitions | 453 | 1 |
| Research Methodology | 454 | 1 |
| Secondary Research | 454 | 1 |
| About GlobalData | 455 | 1 |
| Contact Us | 455 | 1 |
| Disclaimer | 455 | 1 |
| Source | 456 | 1 |